Why Merck & Co. Can't Rest Easy On Its Throne
Merck & Co. Inc. has spent the past several months vanquishing its rivals in the market for immune-boosting cancer drugs.
It just got a reminder that its perch is a shaky one. Merck on Thursday broke an 11-quarter streak of beating earnings forecasts by reporting fourth-quarter results that merely met expectations.
It just got a reminder that its perch is a shaky one. Merck on Thursday broke an 11-quarter streak of beating earnings forecasts by reporting fourth-quarter results that merely met expectations.